Page 1591 - Small Animal Internal Medicine, 6th Edition

Index 1563

Immune-mediated thrombocytopenia Infective endocarditis Insulin (Continued) Intestinal diseases (Continued)
(Continued) antibiotics for, 136–137 short duration of effect, 826, coccidiosis, 488
feline, 1244 antimicrobial prophylaxis for, 138 Somogyi response, 825–826, 826f cryptosporidia, 488–489
826f–827f, 839
VetBooks.ir physical examination of, 1240, 1242f blood culture testing for, 133–134 storage of, 814 dietary-responsive large intestinal
diarrhea. see Diarrhea
immunosuppressive drugs for, 1243
bacteremia and, 132
in cats, 132
prognosis for, 1244
subcutaneous technique for, 846
diarrhea, 494
supportive care for, 1243–1244
clinical features of, 133
treatment of, 1243 cephalosporins for, 136–137 during surgery, 823–824, 837 dietary-responsive small intestinal
diarrhea, 491–492
treatment regimen, 825
Immunodeficiency virus. see Feline congestive heart failure secondary to, types of, 812, 813t elokomin fluke fever, 480
immunodeficiency virus 132 underdosing of, 825–826, 839 enterotoxemia, 475
Immunofluorescence, 1218 diagnosis of, 133–136, 135b Insulin aspart, 812 exocrine pancreatic insufficiency, 413,
Immunoglobulin G, 1346–1348 in dogs, 132 Insulin detemir, 812–814, 813t, 837 491
Immunohistochemistry, 1218 Doppler imaging of, 136, 136f Insulin glargine, 812–814, 813t, 837 feline coronaviral enteritis, 479
Immunopathologic mechanisms, echocardiography of, 133–134, 136f Insulin Lente, 813t, 846 feline immunodeficiency virus-
1211–1212, 1212t–1213t etiology of, 132–133 Insulin lispro, 812, 813t, 846 associated diarrhea, 480
Immunoproliferative enteropathy of immune-mediated disease versus, 133 Insulin NPH, 813t feline leukemia virus-panleukopenia-
basenjis, 497 laboratory tests for, 134 Insulin resistance like syndrome, 479–480
Immunosuppressive drugs, 442 microorganisms associated with, 132 in cats, 836–837, 839 feline parvoviral enteritis, 478–479
chronic hepatitis treated with, neutrophilia associated with, 134 in dogs, 817, 817b, 827–828 giardiasis, 489–490, 489f
592–593 nonregenerative anemia associated ketogenesis and, 840 heterobilharzia, 491
complications of, 1237 with, 134 Insulin-binding antibodies, 828 histoplasmosis, 483–484, 484f
glomerular disease treated with, 682, pathophysiology of, 132–133 Insulin-like factor, 990 hookworms, 487
683b prognosis for, 136–138 Insulin-like growth factor, 749–750, 752f infectious diarrhea, 476–480
hemolysis prevention using, 1235 prophylactic antibiotics for, 138 Insulinoma polyneuropathy, 1165 inflammatory bowel disease. see
immune-mediated disorders treated sequelae of, 134b Insulin-secreting β-cell neoplasia, 808, Inflammatory bowel disease
with, 1220–1221 signs of, 133 847–853 intussusception. see Intussusception
immune-mediated hemolytic anemia systemic effects of, 134b clinical features of, 848–849 large intestinal inflammatory bowel
treated with, 1237 thromboemboli caused by, 133 clinical pathology of, 848–849 disease, 494–495
immune-mediated thrombocytopenia treatment of, 136–138 clinical signs of, 848 maldigestive disease, 491
treated with, 1243 valves commonly affected by, 132 diagnosis of, 849–850, 849f miscellaneous bacteria, 483
Imodium. see Loperamide vegetations associated with, 132 etiology of, 847 protothecosis, 484, 485f
Impression smears, 1258 Infective myocarditis, 153–154 peripheral neuropathy, 848 pythiosis, 484
Imuran. see Azathioprine Infertility physical examination of, 848 roundworms, 486–487, 486f
Inappetence, 72 congenital, 1005 signalment for, 848 salmon poisoning, 480
Incarcerated intestinal obstruction, male. see Male infertility signs associated with, 848b salmonellosis, 481–482
498–499, 499f sexual differentiation disorders, treatment of, 850–852 strongyloidiasis, 488
Incidental adrenal mass, 892–893, 1005–1006, 1006f diazoxide therapy, 850b, 852 tapeworms, 487–488
893f–894f Infiltrative diseases feedings, 852 trichomoniasis, 490–491, 490f
Incurin. see Estriol gastric, 471–472 glucocorticoid therapy, 852 whipworms, 485–486, 485f
Infectious agents gastrointestinal ulceration/erosion overview of, 850 Intestinal distention, 420f
description of, 1427 from, 470 postoperative complications, Intestinal leiomyoma, 503
laboratory diagnosis of, fecal Infiltrative splenomegaly, 1412t, 1413 851–852, 851f Intestinal lymphangiectasia, 495–497,
examination, 1427–1429 Inflammatory bowel disease, 493–495 prognosis for, 853 496f
Infectious diarrhea, 476–480 endoscopy of, 428f somatostatin therapy, 852 Intestinal obstruction, 498–502
canine coronaviral enteritis, 479 Inflammatory myopathies, 1174–1178 streptozotocin therapy, 852 cecocolic intussusception, 501–502
canine parvoviral enteritis, 476–478, Influenza, canine, 340, 1455 surgery, 850–851, 850b, 851f description of, 419, 420f
477b Influenza A viral infections, 1542 Interceptor. see Milbemycin incarcerated, 498–499, 499f
elokomin fluke fever, 480 Injection site sarcomas, 1334–1335, Interestrus intussusception, 501, 501f
feline coronaviral enteritis, 479 1335f definition of, 949 linear foreign objects, 499–501, 500f
feline immunodeficiency virus- Innocent murmurs, 9, 100 prolonged, 955 mesenteric torsion/volvulus, 499
associated diarrhea, 480 Inosine monophosphate dehydrogenase, shortened, 956–957 simple, 498
feline leukemia virus-panleukopenia- 1227 Interferon omega, 515t–517t Intestinal “protectants,”, 440
like syndrome, 479–480 Inotropic agents, for heart failure, 63–65, Intermittent weakness, 2–3, 2b Intoxication(s)
feline parvoviral enteritis, 478–479 69–70 Internal nares, 251f citrate, 1358
salmon poisoning, 480 Insulin International normalization ratio, 233 ethylene glycol, 671, 1099b
Infectious diseases allergic reactions to, 827 Interstitial pattern, 292–293, 292f, mentation abnormalities caused by,
antemortem diagnosis of, 1435 antibodies to, 828 292b–293b 1074
antibody detection complications of, 824–828, 837–839 Intervertebral disk disease seizures caused by, 1099b
in body fluids, 1434–1435 diabetes mellitus managed with acute treatment of, 1100b
in serum, 1433–1434 in cats, 834–836 cervical disk extrusion, 1139 Intraabdominal lymphoma, 1299
biosecurity procedures for small in dogs, 812–814, 813t, 814–816, clinical features of, 1136, 1136f Intracardiac shunt, 109–112
animals hospitals, 1448–1450, 815f, 815t description of, 1135–1141 Intracellular fluid, 844f
1449b diabetic ketoacidosis treated with, diagnostic approach, 1136–1137, Intracranial disorders, 1074–1083
disinfection protocols for, 1450 842b, 845–846 1137f–1139f cerebellar cortical degeneration,
laboratory diagnosis of, 1427–1435 dilution of, 814 magnetic resonance imaging of, 1080–1081
animal inoculation, 1433 disorders causing resistance to, 1137 cerebellar hypoplasia, 1080
culture techniques, 1431–1432 827–828, 828b medical management of, 1139 considerations in, 1074
cytology, 1429–1430 dosage of, 934t myelography for, 1137, 1138f degenerative disorders of brain, 1080
electron microscopy, 1433 duration of effect, 826–827, 826f–827f, treatment of, 1137–1141 diagnostic approach to, 1075, 1075b
immunocytochemistry, 1432 839 type II, 1148 disorders causing, 1075b
immunologic techniques, 1432 endocrine disorders treated with, Intervertebral disks, 1135–1136, 1135f encephalitis, 1080
molecular diagnostics, 1432–1433 896t–897t Intestinal adenocarcinoma, 503 feline hippocampal necrosis,
polymerase chain reaction, hypoglycemia and, 824, 837–838 Intestinal diseases, 474–509 1077–1078
1432–1433, 1432f inadequate absorption of, 827 acute enteritis, 474–475 feline ischemic encephalopathy, 1077
tissue techniques, 1430–1431 initial requirements for, 817–818 acute hemorrhagic diarrheal head trauma, 1075–1076
prevention of initiating of, 846 syndrome, 482–483 hydrocephalus, 1078–1080,
in hospitalized patients, 1449–1450 intermittent intramuscular regimen alimentary tract parasites, 485–491 1078f–1079f
overview of, 1448–1456 for, 846 antibiotic-responsive enteropathy, 442 hypermetria, 1074–1075
patient evaluation, 1449 longer-acting, 846 antibiotic-responsive small intestinal hypertensive encephalopathy, 1077
screening, 936b overdosing of, 825–826, 826f, 836–837 enteropathy, 492 intoxications, 1074
zoonotic transfer of, 1449 prolonged duration of effect, 826–827, campylobacteriosis, 480–481 lissencephaly, 1080
Infectious inflammatory disease, 827f, 839 canine coronaviral enteritis, 479 management of, 1076b
1142–1143 rapid-acting, 812 canine parvoviral enteritis, 476–478, mentation abnormalities, 1074
Infectious orchitis, 1000–1001 recommendations for 477b metabolic encephalopathies, 1074
Infectious pericarditis, 182 in diabetic cats, 834 clostridial colitis, 494 neoplasia, 1081–1082, 1082f
Infectious prostatitis, 1002–1003, 1002f in diabetic dogs, 814 clostridial diseases, 482, 482f neuroaxonal dystrophy, 1080